248 related articles for article (PubMed ID: 25658827)
1. Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo.
Ma J; Duffy MR; Deng L; Dakin RS; Uil T; Custers J; Kelly SM; McVey JH; Nicklin SA; Baker AH
PLoS Pathog; 2015 Feb; 11(2):e1004673. PubMed ID: 25658827
[TBL] [Abstract][Full Text] [Related]
2. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer.
Alba R; Bradshaw AC; Parker AL; Bhella D; Waddington SN; Nicklin SA; van Rooijen N; Custers J; Goudsmit J; Barouch DH; McVey JH; Baker AH
Blood; 2009 Jul; 114(5):965-71. PubMed ID: 19429866
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions.
Bradley RR; Maxfield LF; Lynch DM; Iampietro MJ; Borducchi EN; Barouch DH
J Virol; 2012 Jan; 86(2):1267-72. PubMed ID: 22072746
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection.
Bradley RR; Lynch DM; Iampietro MJ; Borducchi EN; Barouch DH
J Virol; 2012 Jan; 86(1):625-9. PubMed ID: 22072776
[TBL] [Abstract][Full Text] [Related]
5. Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy.
Short JJ; Rivera AA; Wu H; Walter MR; Yamamoto M; Mathis JM; Curiel DT
Mol Cancer Ther; 2010 Sep; 9(9):2536-44. PubMed ID: 20736345
[TBL] [Abstract][Full Text] [Related]
6. Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: Preventing vector clearance and preserving infectivity.
Krutzke L; Prill JM; Engler T; Schmidt CQ; Xu Z; Byrnes AP; Simmet T; Kreppel F
J Control Release; 2016 Aug; 235():379-392. PubMed ID: 27302248
[TBL] [Abstract][Full Text] [Related]
7. The relevance of coagulation factor X protection of adenoviruses in human sera.
Duffy MR; Doszpoly A; Turner G; Nicklin SA; Baker AH
Gene Ther; 2016 Jul; 23(7):592-6. PubMed ID: 27014840
[TBL] [Abstract][Full Text] [Related]
8. Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors.
Bruder JT; Chen P; Semenova E; Thomas CA; Konovalova S; Ekberg G; Ettyreddy D; McVey D; Gall JG; King CR; Brough DE
J Virol; 2013 Sep; 87(17):9661-71. PubMed ID: 23824800
[TBL] [Abstract][Full Text] [Related]
9. Blood Coagulation Factor X Exerts Differential Effects on Adenovirus Entry into Human Lymphocytes.
Findlay JS; Cook GP; Blair GE
Viruses; 2018 Jan; 10(1):. PubMed ID: 29301346
[TBL] [Abstract][Full Text] [Related]
10. Chimeric hexon HVRs protein reflects partial function of adenovirus.
Yu B; Wang C; Dong J; Zhang M; Zhang H; Wu J; Wu Y; Kong W; Yu X
Biochem Biophys Res Commun; 2012 May; 421(2):170-6. PubMed ID: 22490664
[TBL] [Abstract][Full Text] [Related]
11. Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X.
Bradshaw AC; Parker AL; Duffy MR; Coughlan L; van Rooijen N; Kähäri VM; Nicklin SA; Baker AH
PLoS Pathog; 2010 Oct; 6(10):e1001142. PubMed ID: 20949078
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses.
Bradshaw AC; Coughlan L; Miller AM; Alba R; van Rooijen N; Nicklin SA; Baker AH
J Control Release; 2012 Dec; 164(3):394-402. PubMed ID: 22626939
[TBL] [Abstract][Full Text] [Related]
13. Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement.
Xu Z; Qiu Q; Tian J; Smith JS; Conenello GM; Morita T; Byrnes AP
Nat Med; 2013 Apr; 19(4):452-7. PubMed ID: 23524342
[TBL] [Abstract][Full Text] [Related]
14. Hexon hypervariable region-modified adenovirus type 5 (Ad5) vectors display reduced hepatotoxicity but induce T lymphocyte phenotypes similar to Ad5 vectors.
Teigler JE; Penaloza-MacMaster P; Obeng R; Provine NM; Larocca RA; Borducchi EN; Barouch DH
Clin Vaccine Immunol; 2014 Aug; 21(8):1137-44. PubMed ID: 24943382
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors.
Alba R; Bradshaw AC; Coughlan L; Denby L; McDonald RA; Waddington SN; Buckley SM; Greig JA; Parker AL; Miller AM; Wang H; Lieber A; van Rooijen N; McVey JH; Nicklin SA; Baker AH
Blood; 2010 Oct; 116(15):2656-64. PubMed ID: 20610817
[TBL] [Abstract][Full Text] [Related]
16. Genetic strategy to decrease complement activation with adenoviral therapies.
Gentile CM; Borovjagin AV; Richter JR; Jani AH; Wu H; Zinn KR; Warram JM
PLoS One; 2019; 14(4):e0215226. PubMed ID: 31026285
[TBL] [Abstract][Full Text] [Related]
17. Worldwide increased prevalence of human adenovirus type 3 (HAdV-3) respiratory infections is well correlated with heterogeneous hypervariable regions (HVRs) of hexon.
Haque E; Banik U; Monowar T; Anthony L; Adhikary AK
PLoS One; 2018; 13(3):e0194516. PubMed ID: 29590206
[TBL] [Abstract][Full Text] [Related]
18. Human full-length coagulation factor X and a GLA domain-derived 40-mer polypeptide bind to different regions of the adenovirus serotype 5 hexon capsomer.
Sumarheni S; Hong SS; Josserand V; Coll JL; Boulanger P; Schoehn G; Fender P
Hum Gene Ther; 2014 Apr; 25(4):339-49. PubMed ID: 24512117
[TBL] [Abstract][Full Text] [Related]
19. Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors.
Greig JA; Buckley SM; Waddington SN; Parker AL; Bhella D; Pink R; Rahim AA; Morita T; Nicklin SA; McVey JH; Baker AH
Mol Ther; 2009 Oct; 17(10):1683-91. PubMed ID: 19603000
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo.
Kalyuzhniy O; Di Paolo NC; Silvestry M; Hofherr SE; Barry MA; Stewart PL; Shayakhmetov DM
Proc Natl Acad Sci U S A; 2008 Apr; 105(14):5483-8. PubMed ID: 18391209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
